RY 172.7 -0.1792% SHOP 152.38 -3.7762% TD 74.49 -0.4144% ENB 58.66 0.2906% BN 80.21 0.2124% TRI 235.76 -0.7034% CNQ 42.27 -1.3305% CP 102.81 -2.4851% CNR 145.02 -0.9426% BMO 139.15 0.5855% BNS 77.045 -0.149% CSU 4497.2998 0.6756% CM 92.23 -0.335% MFC 43.28 0.8858% ATD 79.0 -1.1882% NGT 53.35 -1.8038% TRP 65.26 0.215% SU 49.61 -1.411% WCN 251.65 -0.2181% L 191.14 0.1205%
Last update at 2024-12-19T18:47:00Z
Masimo Appoints Timothy Scannell and Wendy Lane to Board of Directors
Fri 18 Oct 24, 01:00 PMWhy Masimo (MASI) is a Top Momentum Stock for the Long-Term
Wed 16 Oct 24, 01:50 PMMasimo price target raised to $170 from $166 at BTIG
Tue 15 Oct 24, 11:36 AMHere's Why You Should Add Masimo Stock to Your Portfolio Now
Mon 07 Oct 24, 03:04 PMBest Momentum Stocks to Buy for October 1st
Tue 01 Oct 24, 02:15 PMMasimo Names Interim CEO As Activist Board Members Step In; Joe Kiani Exits Amid Legal Clash
Wed 25 Sep 24, 04:22 PMMasimo Provides Leadership and Business Updates
Wed 25 Sep 24, 01:00 PMMasimo (MASI) Surges 8.7%: Is This an Indication of Further Gains?
Mon 23 Sep 24, 11:46 AMPolitan Comments on Results of Masimo’s 2024 Annual Meeting
Thu 19 Sep 24, 09:39 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 193.40M | 274.38M | 263.74M | 234.17M | 213.78M |
| Minority interest | - | - | -0.02000M | -0.02000M | -0.02000M |
| Net income | 143.50M | 229.65M | 240.30M | 196.22M | 193.54M |
| Selling general administrative | 657.40M | 395.29M | 369.06M | 314.66M | 289.46M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 1058.80M | 808.35M | 743.07M | 629.17M | 574.89M |
| Reconciled depreciation | 136.10M | 35.62M | 29.30M | 23.49M | 21.13M |
| Ebit | 210.00M | 275.82M | 255.82M | 221.22M | 208.89M |
| Ebitda | 346.10M | 311.44M | 284.18M | 244.70M | 230.02M |
| Depreciation and amortization | 136.10M | 35.62M | 28.35M | 23.49M | 21.13M |
| Non operating income net other | -16.60000M | -1.44200M | 7.91M | 12.95M | 5.73M |
| Operating income | 210.00M | 275.82M | 255.82M | 221.22M | 208.04M |
| Other operating expenses | 1825.80M | 963.33M | 888.39M | 716.62M | 649.82M |
| Interest expense | 25.70M | 0.35M | 0.34M | 0.33M | 4.88M |
| Tax provision | 49.90M | 44.73M | 23.45M | 37.95M | 20.23M |
| Interest income | 1.80M | 0.94M | 5.53M | 13.92M | - |
| Net interest income | -23.90000M | 0.58M | 5.20M | 13.59M | - |
| Extraordinary items | - | - | - | - | -0.90000M |
| Non recurring | - | - | -0.47400M | - | 0.42M |
| Other items | - | - | - | - | - |
| Income tax expense | 49.90M | 44.73M | 23.45M | 37.95M | 20.23M |
| Total revenue | 2035.80M | 1239.15M | 1143.74M | 937.84M | 858.29M |
| Total operating expenses | 848.80M | 532.52M | 487.72M | 407.96M | 366.42M |
| Cost of revenue | 977.00M | 430.81M | 400.68M | 308.67M | 283.40M |
| Total other income expense net | -16.60000M | -1.44200M | 7.91M | 12.95M | 5.31M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 143.50M | 229.65M | 240.28M | 196.22M | 193.54M |
| Net income applicable to common shares | 143.50M | 229.65M | 240.30M | 196.22M | 193.54M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 3041.50M | 3210.60M | 1887.01M | 1712.55M | 1396.13M |
| Intangible assets | 1204.60M | 722.60M | 72.50M | 73.92M | 27.25M |
| Earning assets | - | - | - | - | - |
| Other current assets | 99.90M | 158.80M | 91.03M | 102.42M | 60.07M |
| Total liab | 1676.70M | 1871.70M | 336.76M | 304.91M | 228.25M |
| Total stockholder equity | 1364.80M | 1338.90M | 1550.24M | 1407.66M | 1167.87M |
| Deferred long term liab | - | 17.10M | 28.09M | 20.08M | 5.26M |
| Other current liab | 222.40M | 238.80M | 134.86M | 118.86M | 87.08M |
| Common stock | 0.10M | 0.10M | 0.06M | 0.06M | 0.05M |
| Capital stock | 0.10M | 0.10M | 0.06M | 0.06M | 0.05M |
| Retained earnings | 1795.80M | 1714.30M | 1570.86M | 1341.23M | 1100.49M |
| Other liab | - | 246.70M | 69.03M | 71.08M | 40.20M |
| Good will | 407.70M | 445.40M | 100.33M | 103.21M | 22.35M |
| Other assets | - | 0.30M | 202.97M | 161.75M | 105.30M |
| Cash | 166.00M | 202.90M | 745.25M | 641.45M | 567.69M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 563.80M | 630.00M | 267.74M | 233.84M | 172.22M |
| Current deferred revenue | 37.40M | 80.60M | 50.88M | 44.94M | 25.94M |
| Net debt | 804.00M | 772.50M | -712.58900M | -607.09900M | -547.20000M |
| Short term debt | 52.50M | 33.80M | 6.37M | 5.97M | 4.65M |
| Short long term debt | 34.30M | 15.10M | - | - | - |
| Short long term debt total | 970.00M | 975.40M | 32.66M | 34.35M | 20.49M |
| Other stockholder equity | -385.80000M | -387.00000M | -15.14200M | 64.96M | 74.04M |
| Property plant equipment | - | 402.50M | 272.79M | 272.51M | 219.55M |
| Total current assets | 1231.90M | 1308.60M | 1238.41M | 1101.16M | 996.06M |
| Long term investments | 9.90M | 13.80M | 13.83M | 8.00M | 6.47M |
| Net tangible assets | - | 631.50M | 1377.41M | 1230.53M | 1118.27M |
| Short term investments | - | - | - | 0.00000M | 120.00M |
| Net receivables | 421.00M | 445.90M | 200.76M | 141.35M | 132.43M |
| Long term debt | 871.70M | 941.60M | - | - | - |
| Inventory | 545.00M | 501.00M | 201.37M | 215.95M | 115.87M |
| Accounts payable | 251.50M | 276.80M | 75.63M | 64.06M | 54.55M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | -0.02000M | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -45.30000M | 11.50M | -5.53000M | 1.41M | -6.71800M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 0.10M | 0.06M | 0.06M | 0.05M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | 1714.30M | 1570.86M | 1341.23M | 1100.49M |
| Treasury stock | - | -1169.20000M | -767.65500M | -638.73600M | -526.58000M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | -506.80000M | 215.20M | 136.53M | 114.38M | 88.47M |
| Deferred long term asset charges | - | - | - | - | 35.97M |
| Non current assets total | 1809.60M | 1902.00M | 648.60M | 611.39M | 400.07M |
| Capital lease obligations | 64.00M | 72.10M | 32.66M | 34.35M | 20.49M |
| Long term debt total | - | 941.60M | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -1057.70000M | -2.60000M | 120.00M | -120.00000M | -26.15200M |
| Change to liabilities | 71.10M | 18.10M | 42.01M | 29.87M | 11.96M |
| Total cashflows from investing activities | -1057.70000M | -37.52900M | -82.78700M | -197.68100M | -26.15200M |
| Net borrowings | 939.20M | 948.50M | 948.50M | 948.50M | - |
| Total cash from financing activities | 520.30M | -122.40400M | -54.30700M | -9.33900M | 25.78M |
| Change to operating activities | -59.80000M | -8.54600M | -17.06000M | -9.29000M | -7.14400M |
| Net income | 143.50M | 229.65M | 240.28M | 196.22M | 193.54M |
| Change in cash | -538.80000M | 103.37M | 76.93M | 15.43M | 237.16M |
| Begin period cash flow | 748.40M | 645.00M | 568.08M | 552.64M | 315.48M |
| End period cash flow | 209.60M | 748.38M | 645.00M | 568.08M | 552.64M |
| Total cash from operating activities | 29.50M | 264.75M | 210.96M | 221.64M | 239.53M |
| Issuance of capital stock | 8.10M | 23.24M | 58.42M | 28.34M | 44.75M |
| Depreciation | 136.10M | 35.62M | 29.30M | 23.49M | 21.13M |
| Other cashflows from investing activities | -1004.90000M | -2.60000M | -130.23800M | -9.30600M | -9.02600M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -155.90000M | 13.49M | -94.43400M | -21.25700M | -1.88500M |
| Change to account receivables | -138.50000M | -60.79900M | -2.22900M | -23.58000M | 10.83M |
| Sale purchase of stock | -401.50000M | -128.91700M | -110.54000M | -37.55500M | -18.47800M |
| Other cashflows from financing activities | 1049.10M | -16.72800M | -2.19100M | -0.12300M | -0.49000M |
| Change to netincome | 10.20M | 30.83M | 37.90M | 34.31M | 19.65M |
| Capital expenditures | 56.30M | 34.93M | 79.96M | 72.49M | 22.68M |
| Change receivables | -138.50000M | -60.79900M | -2.22900M | -23.58000M | 10.83M |
| Cash flows other operating | -38.50000M | -17.17300M | -41.85900M | -17.41200M | -15.70100M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | -507.90000M | 104.82M | 73.87M | 14.62M | 239.16M |
| Change in working capital | -261.80000M | -31.34500M | -96.51600M | -32.37500M | 7.22M |
| Stock based compensation | 47.70M | 44.62M | 42.23M | 39.23M | 27.42M |
| Other non cash items | 3.30M | 1.29M | 0.64M | 1.04M | -1.50600M |
| Free cash flow | -26.80000M | 229.82M | 131.01M | 149.15M | 216.84M |
Sector: Healthcare Industry: Medical Devices
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MASI Masimo Corporation |
-1.2 0.70% | 169.43 | 85.93 | 40.00 | 3.56 | 5.35 | 3.96 | 34.24 |
| ABT Abbott Laboratories |
1.29 1.15% | 113.22 | 37.15 | 23.15 | 4.67 | 4.97 | 4.88 | 19.38 |
| SYK Stryker Corporation |
-0.41 0.11% | 358.76 | 44.07 | 24.94 | 5.51 | 6.12 | 6.05 | 25.73 |
| MDT Medtronic PLC |
0.41 0.51% | 80.44 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| BSX Boston Scientific Corp |
1.08 1.23% | 89.11 | 68.17 | 24.57 | 5.85 | 4.26 | 6.46 | 26.80 |
Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry. It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, Patient SafetyNet Surveillance, SafetyNet, Replica, Iris, MyView, UniView, Uniview: 60, Masimo Sleep, Centroid, and Bridg; and nasal high-flow ventilation, neuromodulation therapeutics, and telehealth solutions. In addition, the company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and home wellness products through e-commerce internet sites, such as masimopersonalhealth.com, amazon.com, and shopify.com. Masimo Corporation was incorporated in 1989 and is headquartered in Irvine, California.
52 Discovery, Irvine, CA, United States, 92618
| Name | Title | Year Born |
|---|---|---|
| Mr. Joseph E. Kiani | Founder, CEO & Chairman | 1965 |
| Mr. Micah Young | Exec. VP of Fin. & CFO | 1979 |
| Mr. Bilal Muhsin | Chief Operating Officer | 1981 |
| Mr. Thomas Samuel McClenahan | Exec. VP, Gen. Counsel & Corp. Sec. | 1973 |
| Mr. Tao Leopold Levy | Exec. VP of Bus. Devel. | 1974 |
| Mr. Yongsam Lee | Exec. VP & Chief Information Officer | 1965 |
| Dr. Steven J. Barker | Chairman of Scientific Advisory Board & Chief Science Officer | 1945 |
| Mr. Eli Kammerman | VP of Bus. Devel. & Investor Relations | NA |
| Mr. Jon Coleman | Pres of Worldwide Sales, Professional Services & Medical Affairs | 1964 |
| Mr. Anand Sampath | Exec. VP of Operations & Clinical Research | 1966 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
CA 
AU
UK
US
NZ
Please wait processing your request...